Previous Article | Next Article 
Journal of Virology, March 2000, p. 2558-2566, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Inhibition of CD3/CD28-Mediated Activation of the
MEK/ERK Signaling Pathway Represses Replication of X4 but Not R5 Human
Immunodeficiency Virus Type 1 in Peripheral Blood CD4+
T Lymphocytes
Waldemar
Popik1,* and
Paula M.
Pitha1,2
Oncology Center1 and
Department of Molecular Biology and
Genetics,2 The Johns Hopkins University School
of Medicine, Baltimore, Maryland 21231
Received 9 September 1999/Accepted 21 December 1999
 |
ABSTRACT |
Binding of human immunodeficiency virus type 1 (HIV-1) to CD4
receptors induces multiple cellular signaling pathways, including the
MEK/ERK cascade. While the interaction of X4 HIV-1 with CXCR4 does not
seem to activate this pathway, viruses using CCR5 for entry efficiently
activate MEK/ERK kinases (W. Popik, J. E. Hesselgesser, and
P. M. Pitha, J. Virol. 72:6406-6413, 1998; W. Popik and
P. M. Pitha, Virology 252:210-217, 1998). Since the importance of MEK/ERK in the initial steps of viral replication is poorly understood, we have examined the role of MEK/ERK signaling in the CD3- and CD28
(CD3/CD28)-mediated activation of HIV-1 replication in resting peripheral blood CD4+ T lymphocytes infected with X4 or R5
HIV-1. We have found that the MEK/ERK inhibitor U0126 selectively
inhibited CD3/CD28-stimulated replication of X4 HIV-1, while it did not
affect the replication of R5 HIV-1. Inhibition of the
CD3/CD28-stimulated MEK/ERK pathway did not affect the formation of the
early proviral transcripts in cells infected with either X4 or R5
HIV-1, indicating that virus reverse transcription is not affected in
the absence of MEK/ERK signaling. In contrast, the levels of nuclear
provirus in cells infected with X4 HIV-1, detected by the formation of circular proviral DNA, was significantly lower in cells stimulated in
the presence of MEK/ERK inhibitor than in the absence of the inhibitor.
However, in cells infected with R5 HIV-1, the inhibition of the MEK/ERK
pathway did not affect nuclear localization of the proviral DNA. These
data suggest that the nuclear import of X4, but not R5, HIV-1 is
dependent on a CD3/CD28-stimulated MEK/ERK pathway.
 |
INTRODUCTION |
CCR5-specific (R5) strains of human
immunodeficiency virus type 1 (HIV-1) have been implicated in the
transmission of virus infection and are predominantly found during the
asymptomatic stages of HIV infection (31, 42). In contrast,
X4 strains that use CXCR4 coreceptors for entry are generally
associated with disease progression, decline in peripheral
CD4+ T-lymphocyte levels, and the onset of clinical
symptoms of AIDS (9).
Cellular tropism of HIV-1 is primarily determined by utilization of
chemokine receptors. Changes in HIV-1 coreceptor utilization usually
correlate with changes in the V3 loop of the viral envelope glycoprotein (9, 29). In addition to the role that chemokine receptors play as HIV-1 entry cofactors, these receptors are able to
activate different signaling pathways upon interaction with HIV-1
envelope during entry. However, the role of HIV-1-induced signaling
pathways in viral pathogenesis is not clear.
While chemokine receptor signaling in established cell lines is not
necessary for viral entry (1, 12, 14), signaling events seem
to play a role in postentry events (6), aberrant expression
of inflammatory genes (25), CD4+ T-cell
depletion (24), and deregulated cell adhesion and chemotaxis during HIV infection (8). It was shown that binding of HIV-1 envelope glycoproteins from X4 or R5 viruses to chemokine receptors rapidly induced phosphorylation of the tyrosine kinase Pyk2 (10, 23). In addition, macrophage-tropic HIV-1 and simian
immunodeficiency virus (SIV) induced calcium signaling through the CCR5
receptor (38). Recently, R5 HIV-1 envelope was shown to
induce tyrosine phosphorylation of focal adhesion kinase (FAK) and its
association with the CCR5 receptor (8). However, due to the
structural complexity of the chemokine receptors, signaling events
induced by the interaction with specific ligands may not be mimicked
entirely by binding of HIV-1. Specifically, binding of SDF-1, a natural ligand for CXCR4, stimulates the mitogen-activated protein kinase (MAPK) ERK pathway; however, interaction of X4 HIV-1 with CXCR4 did not
activate this pathway (23, 25). In contrast, viruses using
CCR5 for entry efficiently activated MEK/ERK, as well as JNK and p38
MAPKs (26).
The role of MAPK ERK in the HIV-1 life cycle is not completely
understood. Thus, it has been suggested that ERK pathway plays a role
in HIV-1 replication by enhancing the infectivity of virions through
Vif-dependent (39) and Vif-independent mechanisms (18, 40), possibly by the establishment of a functional reverse
transcription complex. In this regard, ERK was shown to phosphorylate
HIV-1 Gag matrix protein p17 (4), which then, together with
Vpr, promotes nuclear translocation of a preintegration complex and, consequently, stimulates virus infectivity.
Activation of CD4+ T cells is critical for efficient
replication of HIV-1 in these cells. In quiescent T cells, HIV-1 entry occurs efficiently; however, the extent of postentry events in quiescent cells is not clear (33, 35, 41). Optimal T-cell activation through T-cell receptor (TCR)/CD28 was shown to be required
for efficient reverse transcription and productive HIV-1 infection
(21, 35). However, the possibility that activation of
signaling cascades upon engagement of CD4 or chemokine coreceptors by
HIV-1 may bypass a requirement for a full T-cell activation for virus
replication has not been considered.
Based on the differential ability of R5 and X4 HIV-1 to induce the
MEK/ERK pathway, which constitutes a part of the TCR/CD28-mediated signaling involved in T-cell activation, we hypothesize that R5 viruses
may be able to replicate and spread in suboptimally activated CD4+ T cells. Interestingly, recent findings showed a
significant replicative advantage of R5 over X4 HIV-1 in suboptimally
activated T lymphocytes (37). Similarly, recent results
obtained in a hu-PBL-SCID mice model showed that X4 HIV-1 strains were
highly virulent when injected at the time the transferred human T cells were highly activated and were less infectious and poorly cytopathic when the majority of T cells at the moment of viral infection were
quiescent or memory cells. In contrast, R5 HIV-1 was virulent independently of the state of target cell activation in the SCID mouse
environment (13).
In the present study, we have investigated the role of MEK/ERK
signaling in CD3 and CD28 (CD3/CD28)-stimulated HIV-1 replication in
resting peripheral blood CD4+ T lymphocytes infected with
X4 or R5 HIV-1. We have shown that in cells stimulated by cross-linking
of CD3 and CD28 receptors, R5, but not X4, HIV-1 replicated efficiently
in the presence of a MEK/ERK inhibitor. Our results further suggest
that in the absence of MEK/ERK signaling, restricted replication of X4
HIV-1 resulted from inefficient completion of late preintegration steps
and/or nuclear import of preintegration complexes and consequent
inhibition of X4 HIV-1 provirus integration.
 |
MATERIALS AND METHODS |
Reagents.
Phosphospecific antibodies detecting
phosphorylated and total forms of ERK1/2 were purchased from New
England Biolabs. MEK/ERK pathway inhibitor U0126 was purchased from
Promega. RNase-free DNase was obtained from Gibco BRL. Monoclonal
anti-CD3 (clone UCHT1) and anti-CD28 (clone CD28.2) antibodies, as well
as control immunoglobulin G1 (IgG1), were obtained from Sigma.
Anti-HLA-DR (clone G46-6) antibody was purchased from Pharmingen.
Isolation and purification of primary CD4+ T
lymphocytes.
Highly enriched preparations of CD4+ T
lymphocytes were isolated from peripheral blood of healthy,
HIV-seronegative donors. Lymphocytes obtained by using LSM lymphocyte
separation medium (Organon Teknika) were depleted of
monocytes/macrophages by 2 h of adherence to plastic in the
presence of 2% of human heat-inactivated AB serum (Sigma). Depletion
of monocytes was repeated two more times. CD4+ T
lymphocytes were isolated by a negative selection with a human T-cell
CD4 subset column kit (R&D Systems) and subsequently incubated with
monoclonal antibody against activation marker HLA-DR (Pharmingen). Positively selected cells expressing HLA-DR were removed by using antimouse antibody-conjugated magnetic beads (Dynal). The isolated resting CD4+ T cells were cultured overnight at 37°C in
RPMI 1640 medium with 2 mM L-glutamine (Life Technologies)
and supplemented with gentamicin (50 µg/ml) and heat-inactivated 5%
human AB serum.
Virus preparation and infection.
Virus stocks of the
infectious X4 NL4-3 and R5 Ba-L and 49-5 clones of HIV-1 were prepared
as described previously (25, 26). The culture supernatants
containing viruses were collected and clarified by centrifugation at
1,500 × g for 15 min, filtered through a
0.45-µm-pore-diameter filter, and frozen at
80°C. Before infection, virus preparations were treated with RNase-free DNase (200 U/ml) for 1 h at room temperature to eliminate potential contamination with viral DNA. The virus titer was monitored by the
reverse transcriptase (RT) activity assay (25, 26).
CD4+ T lymphocytes were infected by incubation with NL4-3,
Ba-L, or 49-5 HIV-1 (20 RT cpm/cell) for 3 h at 37°C, followed
by extensive washing to remove unbound virus. After the infection, the
resting cells were cultured for 3 days in RPMI medium with 5% human
serum without any stimulation. Before stimulation with anti-CD3/CD28 antibodies, the cells were washed, centrifuged, and resuspended in a
fresh culture medium at 0.5 × 106 cells/ml.
Stimulation of HIV-1 replication in infected resting
CD4+ T cells.
The infected CD4+ T cells
were stimulated by cross-linking of CD3 and CD28 receptors by
incubation in six-well plates precoated with monoclonal anti-CD3 (clone
UCHT-1; Sigma) and anti-CD28 (clone CD28.2; Sigma) antibodies prebound
to plastic-immobilized goat antimouse Ig (Sigma) as described
previously (32). In unstimulated controls, cells were
exposed to isotype-matched control IgG1. To study the effect of MEK/ERK
inhibition, a specific inhibitor, U0126 (10 µM in 0.1% dimethyl
sulfoxide), was preincubated with cells at 37°C for 15 min before
being added to plates and stimulated with anti-CD3/CD28 antibodies.
Cells stimulated without the inhibitor were exposed to 0.1% dimethyl sulfoxide.
Western blot analysis.
Cells were solubilized in ice-cold
1% Triton X-100 lysis buffer supplemented with protease and
phosphatase inhibitors as described previously (25). After
30 min on ice, the lysates were clarified by centrifugation, and the
protein concentration was determined with the Pierce bicinchoninic acid
protein assay reagent. Proteins (20 µg) were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (10%
acrylamide), transferred to nitrocellulose membranes, and probed with
specific antibodies (diluted 1:1,000), followed by incubation with
secondary horseradish peroxidase-conjugated antibody (1:100,000). Bound
antibodies were detected with the SuperSignal ULTRA chemiluminescent
substrate (Pierce).
RT-PCR analysis of CD4 and chemokine receptor expression.
Total RNA was isolated from cells with the RNeasy RNA purification
system (Qiagen), and 1 µg of DNase-treated RNA was used for cDNA
synthesis with Superscript II RNase H
RT and
oligo(dT)12-18 primers (Gibco BRL). One-tenth of this
reaction was used as a template for PCR amplification with Taq polymerase (SuperMix; Gibco BRL). The primers for CXCR4,
CCR5, CD4, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were described previously (26). Amplifications were performed for 30 cycles (94°C for 45 s, 50°C for 1 min, and 72°C for 1.5 min), and PCR products were resolved by electrophoresis in a 2%
agarose gel and visualized by ethidium bromide staining.
Flow cytometry.
Expression of CD4 and CXCR4 on purified
CD4+ T lymphocytes was determined by fluorescence-activated
cell sorter (FACS) as described previously (32). The
following antibodies were used: fluorescein isothiocyanate
(FITC)-conjugated antihuman CD4 monoclonal antibody (Becton Dickinson),
phycoerythrin (PE)-conjugated antihuman CXCR4 antibody 12G5
(Pharmingen), and FITC- and PE-conjugated mouse IgG isotype controls.
After being washed twice, the cells were examined with an Epics Elite
FACS (Coulter).
PCR analysis of HIV-1 DNA.
Cells (1 × 106
to 1.5 × 106) were lysed with 200 µl of PCR buffer
consisting of 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 2.5 mM
MgCl2, 0.1 mg of gelatin per ml, 0.45% Nonidet P-40,
0.45% Tween 20, and 100 µg of proteinase K per ml. After protein
digestion for 2 h at 56°C and inactivation for 10 min at 95°C,
different amounts of cell lysate (0.3 to 5µl) were subjected to 25 to
30 cycles of PCR with Taq polymerase in a total volume of 50 µl containing 0.2 µM oligonucleotide primers in PCR SuperMix (Gibco
BRL). The PCR conditions and HIV-1-specific oligonucleotide primers
detecting early R/U5, late long terminal repeat (LTR)/gag,
and 2LTR DNA were described previously (30). Assays for
integrated HIV-1 DNA were performed as described previously
(7). Briefly, the first PCR was carried out by using nested
primers
Alu-LTR 5', specific for conserved sequences of human
Alu; and Alu-LTR 3', from conserved HIV-1 LTR sequences.
Amplifications with serially diluted cells were performed by using
Elongase polymerase (Gibco BRL) for 22 cycles. For the second PCRs,
aliquots of 1, 2, or 5 µl of the 10-fold-diluted first PCR product
were amplified with Taq polymerase for 30 cycles with
primers NI-2 5' and NI-2 3', detecting part of the HIV-1 LTR as
described previously (7). PCR products were analyzed by
electrophoresis in 2% agarose gel and visualized by ethidium bromide staining.
 |
RESULTS |
Establishment of X4 and R5 HIV-1 infection in resting
CD4+ T lymphocytes.
We have earlier shown that X4 and
R5 HIV-1 differ in their ability to activate the MEK/ERK signaling
pathway during interaction with specific chemokine coreceptors
(25). These observations prompted us to investigate the
significance of MEK/ERK pathway activation in the induction of X4 and
R5 virus replication in resting CD4+ T cells. For this
purpose, we have established a resting CD4+ T-cell model of
HIV-1 infection.
Negatively selected CD4+ T lymphocytes were purified from
the peripheral blood of HIV-seronegative donors. Purified T cells were
then cultured for 24 h in the absence of any activation. Subsequently, the cells were either left uninfected or were incubated for 3 h with X4 NL4-3 or R5 Ba-L HIV-1 and then washed extensively to remove unbound virus. After infection, the cells were cultured for 3 days without any stimulation. No virus production, as measured by the
RT assay, could be detected in culture medium during this time.
To measure the efficiency of HIV-1 entry into resting CD4
+
T cells, we first examined by RT-PCR analysis the expression of
CD4 and
CXCR4 and CCR5, which serve as major HIV-1 entry coreceptors
used by
NL4-3 and Ba-L, respectively. We have found that the expression
of CD4
as well as CXCR4 and CCR5 mRNA did not change noticeably
in
unstimulated cells 3 days after infection with X4 and R5 HIV-1
(data
not shown). Synthesis of strong-stop DNA, the early product
of HIV-1
reverse transcription (LTR R/U5 region) synthesized shortly
after viral
entry, was detected only in infected cells (Fig.
1A),
and the levels of R/U5 products
synthesized after entry of X4
NL4-3 and R5 Ba-L were similar. This
suggests that both viruses
entered the cells with comparable
efficiency. Specificity of the
R/U5 signal was confirmed by showing the
persistence of the signal
in unstimulated cells for at least 3 days
after infection (see
Fig.
5). In addition, we did not detect any R/U5
signal in cells
infected with X4 NL4-3 in the presence of AMD3100, an
antagonist
of CXCR4 known to inhibit X4 HIV-1 entry (
11), or
in cells pretreated
with anti-CD4 antibody Q4120, which blocks
CD4-mediated HIV-1
entry (Fig.
1B).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
HIV-1 entry into resting peripheral blood
CD4+ T lymphocytes. (A) HIV-1 entry into unstimulated
CD4+ T lymphocytes. The cells were infected for 3 h
with NL4-3 or Ba-L (20 RT cpm/cell) or were left uninfected. PCR
amplification of total-cell lysates was performed with R/U5 primers
specific for strong-stop DNA as described in Materials and Methods.
Amplification of the -globin gene was used to control the amount of
DNA in each sample. PCR products were resolved by electrophoresis in
2.5% agarose gels and stained with ethidium bromide. (B) Inhibition of
X4 HIV-1 entry into CD4+ T cells by CD4 and CXCR4
antagonists. The cells were preincubated for 30 min with anti-CD4
antibody (5 µg/ml) or AMD3100 (500 ng/ml), followed by infection with
NL4-3 as described for panel A. PCR amplification and analysis of R/U5
product were performed as described for panel A and in Materials and
Methods.
|
|
Restricted replication of X4, but not R5, HIV-1 in resting
CD4+ T cells in the absence of MEK/ERK signaling.
We
next studied the ability of the anti-CD3/anti-CD28 antibodies to
stimulate productive infection in infected resting CD4+ T
cells in which the MEK/ERK pathway was inhibited. The cells, infected
with X4 NL4-3 or R5 Ba-L or with the isogenic pair of HIV-1 strains,
NL4-3 and 49-5, were stimulated with immobilized monoclonal anti-CD3
and anti-CD28 antibodies in the presence or absence of the specific
MEK/ERK pathway inhibitor U0126. Productive replication and the amount
of the virus released into the medium were determined by analysis of RT
activity in culture supernatants. Figure
2A shows that costimulation with
anti-CD3/CD28 antibodies rendered cells competent for productive
infection. At days 3 and 4 after stimulation, replication of Ba-L and
NL4-3 was clearly detected, although the levels of Ba-L HIV-1
replication were initially two- to threefold higher than those of NL4-3
replication. The presence of U0126 did not significantly affect the
replication of R5 HIV-1 Ba-L. In contrast, replication of X4 NL4-3 was
severely inhibited in the presence of MAPK inhibitor. The inhibitory
effect of U0126 on the X4 HIV-1 replication did not result from a
general toxicity of the drug, since replication of Ba-L was not
significantly affected over a period of 9 days.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 2.
Restricted replication of X4 HIV-1 in infected resting
CD4+ T lymphocytes in the absence of MEK/ERK pathway
signaling. Purified peripheral blood CD4+ T lymphocytes
were infected with NL4-3 or Ba-L (A) or with a pair of isogenic
viruses, 49-5 and NL4-3 (B), as described in Materials and Methods.
Subsequently, the cells were left untreated or were stimulated with
immobilized anti-CD3/CD28 antibodies in the absence or presence of
U0126 inhibitor (10 µM). Virus production was monitored by the RT
activity released into culture medium.
|
|
To provide more definitive evidence for the role of R5 and X4 HIV-1
envelopes in the observed effect and to exclude possible
effects of
other viral determinants, we used a pair of isogenic
viruses, NL4-3 and
49-5, which differ exclusively in the envelope
region. A recombinant
clone, 49-5 (
24), is based on X4 NL4-3
and contains the
envelope V3 loop sequence derived from R5 Ba-L
HIV-1. The results
presented in Fig.
2B show that, in contrast
to X4 NL4-3, replication of
R5 49-5 HIV-1, which uses CCR5 for
entry (
24), was not
significantly inhibited in the presence
of the MEK/ERK inhibitor.
Together, these results suggest that
the MEK/ERK activity stimulated by
CD3/CD28 is required to support
viral replication and productive
infection of X4 HIV-1.
To ensure that U0126 inhibits the MEK/ERK pathway in CD4
+ T
cells and to exclude the possibility that ERK activity may be
differentially
altered upon infection, we examined the phosphorylation
status
of ERK1/2 in uninfected cells as well as in cells infected with
Ba-L and NL4-3. The cells were preincubated for 30 min without
or with
U0126 at 10 µM and activated with immobilized anti-CD3/CD28
antibodies for 24 h, and then ERK1/2 phosphorylation was assessed
in cell lysates by Western blot analysis with phosphospecific
antibodies. Figure
3 shows that U0126
significantly inhibited
phosphorylation and activation of ERK1/2. In
addition, we did
not observe any significant changes in the activation
of ERK by
anti-CD3/CD28 antibodies in infected cells.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
U0126 inhibits ERK1/2 phosphorylation induced by CD3 and
CD28 ligation in CD4+ T lymphocytes. Purified peripheral
blood CD4+ T cells (uninfected) were preincubated for 30 min at 37°C in the absence or presence of MEK/ERK inhibitor U0126 (10 µM). Cells infected with Ba-L or NL4-3, as well as the uninfected
cells preincubated in the absence of U0126, were subsequently activated
with plastic-immobilized monoclonal anti-CD3/CD28 antibodies or were
left unactivated. Cells preincubated with U0126 were activated with
immobilized anti-CD3/CD28 antibodies for 24 h in the presence of
the inhibitor before lysis. Triton X-100 cell lysates were prepared,
and proteins (20 µg/lane) were resolved by SDS-PAGE, transferred to a
nitrocellulose membrane, and probed with antibodies specific for
phosphorylated forms of ERK1/2 (P-ERK1/2) and total ERK1/2.
|
|
Restricted replication of X4 NL4-3 does not result from
downregulation of CD4 or CXCR4 expression.
To examine whether the
observed restriction of NL4-3 replication can be ascribed to the
downregulation of CD4 and/or CXCR4 receptors by the inhibitor, we first
analyzed the expression of HIV-1 receptor and coreceptor mRNAs by
RT-PCR in cells infected with NL4-3. For comparison, we also analyzed
the expression of HIV-1 receptor mRNAs in cells infected with Ba-L
HIV-1. Figure 4A shows that the presence
of U0126 did not affect significantly the expression of CD4 or CXCR4
mRNA after stimulation of the cells with anti-CD3/CD28 antibodies over
a period of 6 days. In addition, no major differences in the expression
of CCR5 coreceptor were detected. Since the expression of HIV-1
receptors could be altered by posttranscriptional mechanisms, we
analyzed the cell surface expression of CD4 and CXCR4 receptors by
FACS.

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of the chemokine and CD4 receptor expression in
HIV-1-infected CD4+ T lymphocytes stimulated with
anti-CD3/CD28 antibodies in the presence or absence of MEK/ERK
signaling. (A) Total RNA was isolated from purified CD4+ T
cells infected with NL4-3 or Ba-L and stimulated for the indicated
period of time with immobilized anti-CD3/CD28 antibodies in the absence
or presence of MEK/ERK inhibitor U0126 (10 µM). PCR analysis was
performed with synthesized cDNA under conditions described in Materials
and Methods. PCR products were resolved by electrophoresis in 2.5%
agarose gels and stained with ethidium bromide. GAPDH mRNA served as an
internal control. (B) FACS analysis of surface expression of CD4 and
CXCR4 in resting CD4+ T lymphocytes. Uninfected resting
CD4+ T cells and cells infected with Ba-L or NL4-3 and
stimulated for 6 days with immobilized anti-CD3/CD28 antibodies in the
absence or presence of U0126 (10 µM) were stained with PE- or
FITC-conjugated monoclonal antibodies and subsequently analyzed as
described in Materials and Methods.
|
|
We have found that in the presence of U0126 inhibitor, surface
expression of CD4 receptors was downregulated by about 51%
in both
uninfected and HIV-1-infected CD4
+ T lymphocytes (Fig.
4B)
and thus seems unlikely to result in
specific inhibition of NL4-3, but
not Ba-L or 49-5, HIV-1 replication.
The surface expression of CXCR4
receptors was not significantly
changed by the inhibitor or infection.
In the presence of the
inhibitor, CXCR4 was expressed at levels of 74 to 117%, compared
with those in controls in the absence of the
inhibitor. We therefore
conclude that restricted replication of X4
NL4-3 in the presence
of MEK/ERK inhibitor does not result from a
specific downregulation
of the expression of CD4 or CXCR4 receptors.
This conclusion is
also underscored by the fact that, in our model, a
significant
portion of the resting cells were infected, and therefore
the
initial replication of HIV-1 should be independent of the level
of
HIV-1 receptor or coreceptor
expression.
In addition, the levels of the earliest reverse transcription products
(R/U5 signal) formed after X4 and R5 HIV-1 entry were
similar in the
absence or presence of U0126 (Fig.
5).
This suggests
that some changes in the surface expression of the HIV-1
receptors
do not play a major role in the observed restricted
replication
of NL4-3 in the presence of MEK/ERK inhibitor.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 5.
Differential effect of the MEK/ERK inhibitor U0126 on
nuclear import and/or integration of X4 and R5 HIV-1 proviral DNA. (A
and B) Analysis of the sequential steps of reverse transcription and
subsequent nuclear import and integration of the proviral DNA was
performed with specific oligonucleotide primer sets and under the
conditions described in Materials and Methods. The peripheral blood
resting CD4+ T lymphocytes infected with Ba-L (A), NL4-3
(B), or with the isogenic pair (49-5 and NL4-3) of HIV-1 strains (C)
were left untreated, were treated with MEK/ERK inhibitor U0126 (10 µM) alone, or were stimulated for different periods of time with
immobilized anti-CD3/CD28 antibodies ( CD3 and CD28) in the
absence or presence of U0126. Subsequently, the cells were harvested
and analyzed by PCR for RT products that were early (RU5), late
(LTRgag), nuclear (2LTR circles), and integrated (INT) into the host
genome, respectively. The amount of total DNA was controlled by
amplification of the cellular -globin gene. (D) As controls, serial
dilutions of the HIV-1-infected ACH-2 cells, containing one HIV-1
provirus per cell, were amplified with the same set of primers. Note
that, in these cells, 2LTR circles were not present.
|
|
Activation of the MEK/ERK signaling pathway is not required for the
early preintegration steps of HIV-1 replication.
To define
MAPK-dependent steps in HIV-1 replication that control establishment of
productive infection in resting CD4+ T lymphocytes, we used
PCR to analyze proviral reverse transcription products. The set of
oligonucleotide primers that can specifically identify different forms
of proviral DNA transcripts was used (7, 30). Infected
CD4+ T cells were collected at different times after
stimulation with anti-CD3/CD28 antibodies, and the first products of
reverse transcription synthesized after viral entry were identified by
amplification of total DNA with the LTR R/U5 primers. It can be seen
that these early proviral transcripts were present in both unstimulated
and stimulated cells infected with either R5 Ba-L (Fig. 5A) or X4 NL4-3
(Fig. 5B) HIV-1. Inhibition of the MAPK pathway by treatment of the
cells with U0126 inhibitor did not affect the levels of the amplified
R/U5 DNA, indicating that the early step of reverse transcription is
independent of the MAPK pathway and CD3/CD28 stimulation. In
unstimulated cells infected with NL4-3, the R/U5 signals significantly
diminished on day 6 (144 h), suggesting that the unintegrated proviral
DNA disappears faster in X4 NL4-3-infected cells than in cells infected
with R5 Ba-L HIV-1.
The LTR/
gag fragments representing DNA formed after the
second template switch were present at 24 h poststimulation in the
CD3/CD28-stimulated cells and the unstimulated controls. The relative
levels of LTR/
gag DNA were not significantly affected by the
presence
of U0126 inhibitor. However, the levels of LTR/
gag
DNA increased
at 72 h after the CD3/CD28 stimulation in both cells
infected
with NL4-3 and those infected with Ba-L and remained increased
over a period of 6 days after stimulation. This contrasts with
the
accumulation of the transcripts in unstimulated cells that
could be
detected on day 6 only in cells infected with Ba-L, but
not those
infected with NL4-3 HIV-1. These results indicate that
in cells
infected with X4 or R5 HIV-1, virus transcription proceeds
almost to
completion, even in the absence of the MAPK signaling
pathway. However,
in unstimulated cells, the levels and/or stability
of preintegration
forms of HIV-1 DNA were significantly higher
in cells infected with R5
than in those infected with X4 HIV-1.
Activation of ERK is required for successful completion of reverse
transcription or nuclear import of X4 NL4-3 proviral DNA in infected
CD4+ T cells.
We further investigated whether
activation of the MEK/ERK pathway induced by engagement of TCR/CD28 is
required for completion of reverse transcription or nuclear import of
X4 HIV-1 DNA. To this end, we monitored the levels of PCR-amplified
circular proviral DNA (2LTR signal) as a marker for full completion of
reverse transcription and translocation of the preintegration complexes
into the nucleus. Since 2LTR viral DNA is formed exclusively in the
nucleus (after synthesis of full-length viral DNA), it is commonly used
as a marker for completion of preintegration steps and nuclear import of HIV-1 DNA (43). The amount of total DNA was controlled by amplifying the cellular
-globin gene. In addition, as a control, cellular lysates from HIV-1-infected ACH-2 cells, containing one integrated HIV-1 provirus per cell, were prepared and amplified with
the same set of primers (Fig. 5D). Figure 5 shows that, in the absence
of CD3/CD28 stimulation, the levels of 2LTR DNA circles were
undetectable in cells infected with NL4-3. However, very faint bands,
corresponding to 2LTR circles, could be detected at 24 h
poststimulation in cells infected with Ba-L.
Formation of 2LTR circles was detected in infected cells stimulated for
at least 72 h with anti-CD3/CD28 antibodies. However,
in
CD4
+ T cells infected with X4 NL4-3 and stimulated through
TCR/CD28
in the presence of MEK/ERK inhibitor, the relative levels of
2LTR
circle signals were significantly lower (about 10-fold [Fig.
5C])
than those in infected cells stimulated in the absence of the
inhibitor. In contrast, in cells infected with Ba-L (Fig.
5A)
or R5
49-5 (Fig.
5C) HIV-1, containing the envelope V3 loop from
Ba-L in the
background of NL4-3, the presence of MEK/ERK inhibitor
did not
significantly affect formation of 2LTR DNA circles. These
results
suggest that full completion of preintegration steps and/or
nuclear
import of X4 HIV-1 DNA, but not R5 HIV-1 provirus, is
significantly
impaired in the presence of MEK/ERK pathway
inhibition.
The levels of integrated HIV-1 DNA were determined by using nested PCR
amplification with Alu-LTR primers in the initial PCR
and a pair of
NI-2 primers, which allows amplification of a portion
of the HIV-1 LTR,
for the second PCR (
7). Integrated DNA was
detected only in
infected cells stimulated for 72 h with anti-CD3/CD28
antibodies.
No integration signal was present in infected unstimulated
cells.
However, a significant difference in integration of Ba-L
and NL4-3
provirus was observed in the cells treated with MEK/ERK
inhibitor.
While the integration of HIV-1 Ba-L DNA was unaffected
in the presence
of U0126 inhibitor, integration of NL4-3 DNA was
greatly inhibited.
Since we have shown that the completion of
the preintegration steps of
NL4-3 HIV-1 provirus is significantly
inhibited by the MEK/ERK
inhibitor, we assume that, as a consequence,
integration of the
provirus is inhibited as well. However, it
is not clear whether the
MEK/ERK pathway directly regulates the
process of integration of
proviral DNA into the host
genome.
Together, our results suggest that activation of the MAPK ERK pathway
during CD3/CD28 stimulation is necessary for the full
completion of the
preintegration steps and/or nuclear import of
X4 HIV-1 DNA and
replication of the virus in CD4
+ T lymphocytes. In
contrast, CD3/CD28-induced MEK/ERK signaling
is not required for
efficient replication of R5 Ba-L or 49-5 HIV-1
in CD4
+ T
cells. Studies are in progress to delineate the mechanism(s)
responsible for the observed differential requirements for MEK/ERK
signaling for the replication of X4 and R5 HIV-1.
 |
DISCUSSION |
We have shown in this study that replication of R5 HIV-1 in
infected resting peripheral blood CD4+ T lymphocytes
stimulated with anti-CD3/CD28 antibodies is independent of the
stimulation of the MEK/ERK pathway. In contrast, replication of X4
HIV-1 was dependent on the presence of a functional MEK/ERK pathway. We
have further shown that this restricted replication of X4, but not R5,
HIV-1 was a result of inefficient completion of late preintegration
steps and/or nuclear import of proviral DNA.
To mimic the activation of T cells that takes place during antigen
presentation, we have used an in vitro model of resting CD4+ T cells infected with X4 or R5 HIV-1 and subsequently
stimulated by cross-linking of CD3 and CD28 receptors with
plastic-immobilized monoclonal antibodies (32). Importantly,
this stimulation allows for productive replication of both X4 and R5
HIV-1 in the cells. Since it was shown that CD4+ T cells
downregulated CCR5, but not CXCR4, expression in response to CD28
costimulation (27), we used cells that were infected with
HIV-1 before stimulation with anti-CD3/CD28 antibodies. Our results
showed that both X4 and R5 HIV-1 entered the cells with comparable
efficiency in the absence of stimulation, as determined by analysis of
the levels of R/U5 DNA, the product of HIV-1 reverse transcription
synthesized shortly after viral entry.
It is well established that the MEK/ERK pathway constitutes a part of
TCR/CD28-mediated signaling involved in T-cell activation (5) and can be specifically inhibited by the MEK/ERK
inhibitor U0126 (15). Accordingly, we have shown that
stimulation of the resting CD4+ T cells with the
anti-CD3/CD28 antibodies in the presence of U0126 results in a
significant inhibition of ERK phosphorylation and activation (Fig. 3).
In addition, we did not observe any significant changes in the
activation of ERK by the anti-CD3/CD28 antibodies in uninfected and
infected cells. Thus, differential replication of X4 and R5 HIV-1 in
cells stimulated in the presence of U0126 suggests that X4 and R5
viruses may differ in their requirements for the MEK/ERK stimulation
for viral replication. By using a pair of isogenic viruses, X4 NL4-3
and R5 49-5, that differ only in the V3 region of the envelope, we
showed that the observed restricted replication of X4 HIV-1 in the
absence of MEK/ERK signaling can be overcome by changing the HIV-1
coreceptor specificity.
We speculate that the observed differences may be related to
differential signaling induced upon entry of R5 and X4 viruses. In this
regard, we have shown that the interaction of SIVs with CCR5 stimulated
the MEK/ERK pathway (26). In contrast, engagement of CXCR4
by X4 HIV-1 did not induce this pathway (25). However, both
X4 and R5 viruses stimulated the MEK/ERK pathway through CD4 receptor,
independently of signaling through chemokine receptors (3, 25,
26). Interestingly, engagement of CD4 and CCR5 receptors by SIV
significantly enhanced the MEK/ERK as well as JNK and p38 MAPK
signaling, compared to binding to CCR5-negative cells. These results
suggest that CD4 receptor-induced signaling can be significantly
intensified by the engagement of CCR5, but not CXCR4, coreceptors.
Consequently, R5 HIV-1 replication in "preactivated" cells may
require suboptimal activation delivered by the engagement of CD3 and
CD28 receptors in the absence of MEK/ERK activity. In contrast, X4
HIV-1 will require MEK/ERK activity induced by CD3/CD28 receptors for
optimal replication. Whether these quantitative differences in
expression of the MEK/ERK cascade or possible synergistic interaction
with other HIV-1 binding-induced pathways lead to the observed
different outcome for X4 and R5 HIV-1 replication requires further investigation.
Since we performed our experiments with unselected primary
CD4+ T lymphocytes, we cannot exclude the possibility that
the observed effects may be at least partially due to infection of
different CD4+ T-cell subpopulations by X4 and R5 HIV-1.
Two major subsets of CD4+ T cells, naive and memory cells,
differ functionally from each other and show different patterns of
intracellular signaling upon CD3 stimulation (17). However,
previous studies showed that surface expression of the HIV-1
coreceptors on CD4+ T cells was differentially expressed on
naive versus memory T cells, with CCR5 mostly restricted to the CD26
high subset of memory CD45RO+ cells and CXCR4 expressed on
both memory and naive CD45RA+ CD4+ T cells
(2, 22). In addition, it was shown that X4 HIV-1 replicates
preferentially in memory cells (32) and does not replicate
productively in naive cells stimulated with anti-CD3/CD28 antibodies
(28). It therefore seems conceivable that X4 and R5 HIV-1
replicated preferentially in a population of memory cells in our in
vitro system. However, whether the memory cells are the only infected
subset of CD4+ T cells in our system is not clear.
In accordance with our results, it was recently shown that R5 HIV-1 has
a significant replicative advantage over X4 HIV-1 in suboptimally
activated T lymphocytes (37). However, the nature of this
envelope-dependent restriction was not clarified. Similarly, recent
results suggest that R5 and X4 HIV-1 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation of T
cells (13). While X4 strains were highly virulent only when
injected at a time when the transferred human T cells were highly
activated, the R5 HIV-1 strains caused CD4+ T-cell
depletion and immune dysfunction independent of the state of activation
of the target cells.
To define MEK/ERK-dependent steps in the viral life cycle that restrict
replication of X4 HIV-1 in CD4+ T cells, we have used PCR
analysis. In our model, a possible downregulation of HIV-1 receptors
should not have a critical effect early in HIV-1 infection, since
CD4+ T cells were "latently" infected, and thus HIV-1
early replication events did not involve engagement of HIV-1 receptors.
Although we did not find any evidence of a significant modulation of
CD4, CXCR4, or CCR5 at the transcriptional levels, surface expression of the CD4 receptor was decreased by 51% in the presence of MEK/ERK inhibitor. Interestingly, a similar reduction was observed in both
uninfected and infected cells. Together with the observation that CXCR4
coreceptor was not significantly modulated by U0126, changes in the
expression of HIV-1 receptors cannot satisfactorily explain the
observed restriction of the X4 HIV-1 replication in resting
CD4+ T cells.
PCR analysis of the preintegration stages of HIV-1 replication
performed with LTR/gag-specific primers suggested that
reverse transcription proceeded significantly to completion in
CD3/CD28-stimulated infected cells and was independent of MEK/ERK
activation. Using LTR/gag primers, we could not conclude
whether the reverse transcription proceeded to full completion,
resulting in double-stranded and blunt-ended DNAs that serve as the
substrate for HIV-1 integrase. However, the 2LTR circular forms of
viral DNA that are formed exclusively in the nucleus (36)
are used as a marker for full completion of reverse transcription and
translocation of the preintegration complex into the nucleus
(43). Using primers detecting 2LTR circle forms of HIV-1
DNA, we have found that a full completion of preintegration steps
and/or nuclear import of X4 HIV-1 DNA was significantly impaired in the
presence of MEK/ERK inhibitor. In contrast, nuclear import of R5 HIV-1
DNA was not significantly affected by the inhibitor. Similarly,
integration of HIV-1 DNA into the host genome followed the same
pattern. However, it is not clear whether the MEK/ERK pathway directly
regulates some aspects of integration or merely overcomes a primary
block related to full completion of reverse transcription and/or
nuclear import of preintegration complexes.
The nature of the specific MEK/ERK targets that may be involved in
nuclear import of preintegration complexes is not clear. It has been
suggested that phosphorylation of HIV-1 Gag MA protein localized in the
viral reverse transcription complexes is required for nuclear transport
of viral DNA (4). However, whether HIV-1 Gag represents the
only viral target for MEK/ERK is unknown. It seems possible that
cellular factors that serve as MEK/ERK substrates may also be required
for efficient completion of reverse transcription and nuclear import of
preintegration complexes. In this regard, a nuclear factor of activated
T cells, NFATc, was shown to facilitate completion of HIV-1 reverse
transcription (20). Interestingly, regulation of NFATc
in T cells requires the activity of multiple effector pathways,
including ERK (16). In addition, it was suggested that
c-Myc, which is regulated by the MEK/ERK pathway (19), controls HIV-1 DNA nuclear import without an effect on viral
full-length synthesis (34). Further experiments will be
required in order to understand the role of MEK/ERK signaling in X4 and
R5 HIV-1 replication and pathogenesis.
 |
ACKNOWLEDGMENTS |
This study was supported by NIH grants AI42557 (W.P.) and AI40838
(P.M.P.).
We thank B. Chesebro for the HIV-1 49-5 plasmid and D. Schols for the
gift of AMD3100, T. Pierson for help with FACS analysis, and T. Alce
for critical reading of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Oncology Center,
The Johns Hopkins University, 418 N. Bond St., Baltimore, MD
21231-1001. Phone: (410) 955-8873. Fax: (410) 955-0840. E-mail:
wpopik{at}jhmi.edu.
 |
REFERENCES |
| 1.
|
Atchison, R. E.,
J. Gosling,
F. S. Monteclaro,
C. Franci,
L. Digilio,
I. F. Charo, and M. A. Goldsmith.
1996.
Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines.
Science
274:1924-1926[Abstract/Free Full Text].
|
| 2.
|
Bleul, C. C.,
L. Wu,
J. A. Hoxie,
T. A. Springer, and C. R. Mackay.
1997.
The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.
Proc. Natl. Acad. Sci. USA
94:1925-1930[Abstract/Free Full Text].
|
| 3.
|
Briant, L.,
V. Robert-Hebmann,
V. Sivan,
A. Brunet,
J. Pouyssegur, and C. Devaux.
1998.
Involvement of extracellular signal-regulated kinase module in HIV-mediated CD4 signals controlling activation of nuclear factor- B and AP-1 transcription factors.
J. Immunol.
160:1875-1885[Abstract/Free Full Text].
|
| 4.
|
Bukrinskaya, A. G.,
A. Ghorpade,
N. K. Heinzinger,
T. E. Smithgall,
R. E. Lewis, and M. Stevenson.
1996.
Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA.
Proc. Natl. Acad. Sci. USA
93:367-371[Abstract/Free Full Text].
|
| 5.
|
Cantrell, D.
1996.
T cell antigen receptor signal transduction pathways.
Annu. Rev. Immunol.
14:259-274[CrossRef][Medline].
|
| 6.
|
Chackerian, B.,
E. M. Long,
P. A. Luciw, and J. Overbaugh.
1997.
Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection.
J. Virol.
71:3932-3939[Abstract].
|
| 7.
|
Chun, T.-W.,
L. Stuyver,
S. B. Mizell,
A. L. Ehler,
J. A. Mican,
M. Baseler,
A. L. Lloyd,
M. A. Nowak, and A. S. Fauci.
1997.
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.
Proc. Natl. Acad. Sci. USA
94:13193-13197[Abstract/Free Full Text].
|
| 8.
|
Cicala, C.,
J. Arthos,
M. Ruiz,
M. Vaccarezza,
A. Rubbert,
A. Riva,
K. Wildt,
O. Cohen, and A. S. Fauci.
1999.
Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope.
J. Immunol.
163:420-426[Abstract/Free Full Text].
|
| 9.
|
Connor, R. I.,
K. E. Sheridan,
D. Ceradini,
S. Choe, and N. R. Landau.
1997.
Change in coreceptor use correlates with disease progression in HIV-1-infected individuals.
J. Exp. Med.
185:621-628[Abstract/Free Full Text].
|
| 10.
|
Davis, C. B.,
I. Dikic,
D. Unutmaz,
C. M. Hill,
J. Arthos,
M. A. Siani,
D. A. Thompson,
J. Schlessinger, and D. R. Littman.
1997.
Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5.
J. Exp. Med.
186:1793-1798[Abstract/Free Full Text].
|
| 11.
|
Donzella, G. A.,
D. Schols,
S. W. Lin,
J. A. Este,
K. A. Nagashima,
P. J. Maddon,
G. P. Allaway,
T. P. Sakmar,
G. Henson,
E. De Clercq, and J. P. Moore.
1998.
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.
Nat. Med.
4:72-77[CrossRef][Medline].
|
| 12.
|
Doranz, B. J.,
M. J. Orsini,
J. D. Turner,
T. L. Hoffman,
J. F. Berson,
J. A. Hoxie,
S. C. Peiper,
L. F. Brass, and R. W. Doms.
1999.
Identification of CXCR4 domains that support coreceptor and chemokine receptor functions.
J. Virol.
73:2752-2761[Abstract/Free Full Text].
|
| 13.
|
Fais, S.,
C. Lapenta,
S. M. Santini,
M. Spada,
S. Parlato,
M. Logozzi,
P. Rizza, and F. Belardelli.
1999.
Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/differentiation of human target cells at the time of primary infection.
J. Virol.
73:6453-6459[Abstract/Free Full Text].
|
| 14.
|
Farzan, M.,
H. Choe,
K. A. Martin,
Y. Sun,
M. Sidelko,
C. R. Mackay,
N. P. Gerard,
J. Sodroski, and C. Gerard.
1997.
HIV-1 entry and macrophage inflammatory protein-1- -mediated signaling are independent functions of the chemokine receptor CCR5.
J. Biol. Chem.
272:6854-6857[Abstract/Free Full Text].
|
| 15.
|
Favata, M. F.,
K. Y. Horiuchi,
E. J. Manos,
A. J. Daulerio,
D. A. Stradley,
W. S. Feeser,
D. E. Van Dyk,
W. J. Pitts,
R. A. Earl,
F. Hobbs,
R. A. Copeland,
R. L. Magolda,
P. A. Scherle, and J. M. Trzaskos.
1998.
Identification of a novel inhibitor of mitogen-activated protein kinase kinase.
J. Biol. Chem.
273:18623-18632[Abstract/Free Full Text].
|
| 16.
|
Genot, E.,
S. Cleverley,
S. Henning, and D. Cantrell.
1996.
Multiple p21ras effector pathways regulate nuclear factor of activated T cells.
EMBO J.
15:3923-3933[Medline].
|
| 17.
|
Hall, S. R.,
B. M. Heffernan,
N. T. Thompson, and W. C. Rowan.
1999.
CD4+ CD45RA+ and CD4+ CD45RO+ T cells differ in their TCR-associated signaling responses.
Eur. J. Immunol.
29:2098-2106[CrossRef][Medline].
|
| 18.
|
Jacque, J.-M.,
A. Mann,
H. Enslen,
N. Sharova,
B. Brichacek,
R. J. Davis, and M. Stevenson.
1998.
Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase.
EMBO J.
17:2607-2618[CrossRef][Medline].
|
| 19.
|
Kerkhoff, E.,
R. Houben,
S. Loffler,
J. Troppmair,
J. E. Lee, and U. R. Rapp.
1998.
Regulation of c-myc expression by Ras/Raf signalling.
Oncogene
16:211-216[CrossRef][Medline].
|
| 20.
|
Kinoshita, S.,
B. K. Chen,
H. Kaneshima, and G. P. Nolan.
1998.
Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells.
Cell
95:595-604[CrossRef][Medline].
|
| 21.
|
Korin, Y. D., and J. A. Zack.
1998.
Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells.
J. Virol.
72:3161-3168[Abstract/Free Full Text].
|
| 22.
|
Lee, B.,
M. Sharron,
L. J. Montaner,
D. Weissman, and R. W. Doms.
1999.
Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages.
Proc. Natl. Acad. Sci. USA
96:5215-5220[Abstract/Free Full Text].
|
| 23.
|
Misse, D.,
M. Cerutti,
N. Noraz,
P. Jourdan,
J. Favero,
G. Devauchelle,
H. Yssel,
N. Taylor, and F. Veas.
1999.
A CD4-independent interaction of human immunodeficiency virus-1 gp120 with CXCR4 induces their cointernalization, cell signaling, and T-cell chemotaxis.
Blood
93:2454-2462[Abstract/Free Full Text].
|
| 24.
|
Penn, M. L.,
J.-C. Grivel,
B. Schramm,
M. A. Goldsmith, and L. Margolis.
1999.
CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue.
Proc. Natl. Acad. Sci. USA
96:663-668[Abstract/Free Full Text].
|
| 25.
|
Popik, W.,
J. E. Hesselgesser, and P. M. Pitha.
1998.
Binding of human immunodeficiency virus type 1 to CD4 and CXCR4 receptors differentially regulates expression of inflammatory genes and activates the MEK/ERK signaling pathway.
J. Virol.
72:6406-6413[Abstract/Free Full Text].
|
| 26.
|
Popik, W., and P. M. Pitha.
1998.
Early activation of mitogen-activated protein kinase kinase, extracellular signal-regulated kinase, p38 mitogen-activated protein kinase, and c-Jun N-terminal kinase in response to binding of simian immunodeficiency virus to Jurkat T cells expressing CCR5 receptor.
Virology
252:210-217[CrossRef][Medline].
|
| 27.
|
Riley, J. L.,
B. L. Levine,
N. Craighead,
T. Francomano,
D. Kim,
R. G. Carroll, and C. H. June.
1998.
Naïve and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation: implications for transmission and pathogenesis.
J. Virol.
72:8273-8280[Abstract/Free Full Text].
|
| 28.
|
Roederer, M.,
P. A. Raju,
D. K. Mitra,
L. A. Herzenberg, and L. A. Herzenberg.
1997.
HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28.
J. Clin. Investig.
99:1555-1564[Medline].
|
| 29.
|
Scarlatti, G.,
E. Tresoldi,
A. Bjorndal,
R. Fredriksson,
C. Colognesi,
H. K. Deng,
M. S. Malnati,
A. Plebani,
A. G. Siccardi,
D. R. Littman,
E. M. Fenyo, and P. Lusso.
1997.
In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.
Nat. Med.
3:1259-1265[CrossRef][Medline].
|
| 30.
|
Schmidtmayerova, H.,
M. Alfano,
G. Nuovo, and M. Bukrinsky.
1998.
Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level.
J. Virol.
72:4633-4642[Abstract/Free Full Text].
|
| 31.
|
Schuitemaker, H.,
M. Koot,
N. A. Kootstra,
M. W. Dercksen,
R. E. Y. de Goede,
R. P. van Steenwijk,
J. M. A. Lange,
J. K. M. Eeftink Schattenkerk,
F. Miedema, and M. Tersmette.
1992.
Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.
J. Virol.
66:1354-1360[Abstract/Free Full Text].
|
| 32.
|
Spina, C. A.,
H. E. Prince, and D. D. Richman.
1997.
Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro.
J. Clin. Investeg.
99:1774-1785[Medline].
|
| 33.
|
Spina, C. A.,
J. C. Guatelli, and D. D. Richman.
1995.
Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro.
J. Virol.
69:2977-2988[Abstract].
|
| 34.
|
Sun, Y., and E. A. Clark.
1999.
Expression of the c-myc proto-oncogene is essential for HIV-1 infection in activated T cells.
J. Exp. Med.
189:1391-1397[Abstract/Free Full Text].
|
| 35.
|
Sun, Y.,
L. M. Pinchuk,
M. B. Agy, and E. A. Clark.
1997.
Nuclear import of HIV-1 DNA in resting CD4+ T cells requires a cyclosporin A-sensitive pathway.
J. Immunol.
158:512-517[Abstract].
|
| 36.
|
Varmus, H., and R. Swanstrom.
1985.
Replication of retroviruses, p. 369.
In
R. Weiss, N. Teich, H. Varmus, and J. Coffin (ed.), RNA tumor viruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 37.
|
Vicenzi, E.,
P. P. Bordignon,
P. Biswas,
A. Brambilla,
C. Bovolenta,
M. Cota,
F. Sinigaglia, and G. Poli.
1999.
Envelope-dependent restriction of human immunodeficiency virus type 1 spreading in CD4+ T lymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation.
J. Virol.
73:7515-7523[Abstract/Free Full Text].
|
| 38.
|
Weissman, D.,
R. L. Rabin,
J. Arthos,
A. Rubbert,
M. Dybul,
R. Swofford,
S. Venkatesan,
J. M. Farber, and A. S. Fauci.
1997.
Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor.
Nature
389:981-985[CrossRef][Medline].
|
| 39.
|
Yang, X., and D. Gabuzda.
1998.
Mitogen-activated protein kinase phosphorylates and regulates the HIV-1 Vif protein.
J. Biol. Chem.
273:29879-29887[Abstract/Free Full Text].
|
| 40.
|
Yang, X., and D. Gabuzda.
1999.
Regulation of human immunodeficiency virus type 1 infectivity by the ERK mitogen-activated protein kinase signaling pathway.
J. Virol.
73:3460-3466[Abstract/Free Full Text].
|
| 41.
|
Zack, J.,
A. M. Haislip,
P. Krogstad, and I. S. Y. Chen.
1992.
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.
J. Virol.
66:1717-1725[Abstract/Free Full Text].
|
| 42.
|
Zhu, T.,
H. Mo,
N. Wang,
D. S. Nam,
Y. Cao,
R. A. Koup, and D. D. Ho.
1993.
Genotypic and phenotypic characterization of HIV-1 in patients with primary infection.
Science
261:1179-1181.
|
| 43.
|
Zybarth, G.,
N. Reiling,
H. Schmidtmayerova,
B. Sherry, and M. Bukrinsky.
1999.
Activation-induced resistance of human macrophages to HIV-1 infection in vitro.
J. Immunol.
162:400-406[Abstract/Free Full Text].
|
Journal of Virology, March 2000, p. 2558-2566, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Khatua, A. K., Taylor, H. E., Hildreth, J. E. K., Popik, W.
(2009). Exosomes Packaging APOBEC3G Confer Human Immunodeficiency Virus Resistance to Recipient Cells. J. Virol.
83: 512-521
[Abstract]
[Full Text]
-
Melar, M., Ott, D. E., Hope, T. J.
(2007). Physiological Levels of Virion-Associated Human Immunodeficiency Virus Type 1 Envelope Induce Coreceptor-Dependent Calcium Flux. J. Virol.
81: 1773-1785
[Abstract]
[Full Text]
-
Marjuki, H., Alam, M. I., Ehrhardt, C., Wagner, R., Planz, O., Klenk, H.-D., Ludwig, S., Pleschka, S.
(2006). Membrane Accumulation of Influenza A Virus Hemagglutinin Triggers Nuclear Export of the Viral Genome via Protein Kinase C{alpha}-mediated Activation of ERK Signaling. J. Biol. Chem.
281: 16707-16715
[Abstract]
[Full Text]
-
Cicala, C., Arthos, J., Martinelli, E., Censoplano, N., Cruz, C. C., Chung, E., Selig, S. M., Van Ryk, D., Yang, J., Jagannatha, S., Chun, T. W., Ren, P., Lempicki, R. A., Fauci, A. S.
(2006). R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells. Proc. Natl. Acad. Sci. USA
103: 3746-3751
[Abstract]
[Full Text]
-
Doncel, G. F.
(2006). Exploiting common targets in human fertilization and HIV infection: development of novel contraceptive microbicides. Hum Reprod Update
12: 103-117
[Abstract]
[Full Text]
-
Locher, C. P., Witt, S. A., Kassel, R., Dowell, N. L., Fujimura, S., Levy, J. A.
(2005). Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation. J. Gen. Virol.
86: 1171-1179
[Abstract]
[Full Text]
-
Wang, J., Marschner, S., Finkel, T. H.
(2004). CXCR4 engagement is required for HIV-1-induced L-selectin shedding. Blood
103: 1218-1221
[Abstract]
[Full Text]
-
Popik, W., Alce, T. M.
(2004). CD4 Receptor Localized to Non-raft Membrane Microdomains Supports HIV-1 Entry: IDENTIFICATION OF A NOVEL RAFT LOCALIZATION MARKER IN CD4. J. Biol. Chem.
279: 704-712
[Abstract]
[Full Text]
-
Vicenzi, E., Panina-Bodignon, P., Vallanti, G., Di Lucia, P., Poli, G.
(2002). Restricted replication of primary HIV-1 isolates using both CCR5 and CXCR4 in Th2 but not in Th1 CD4+ T cells. J. Leukoc. Biol.
72: 913-920
[Abstract]
[Full Text]
-
Twu, C., Liu, N. Q., Popik, W., Bukrinsky, M., Sayre, J., Roberts, J., Rania, S., Bramhandam, V., Roos, K. P., MacLellan, W. R., Fiala, M.
(2002). Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways. Proc. Natl. Acad. Sci. USA
99: 14386-14391
[Abstract]
[Full Text]
-
Konig, R. R., Flory, E., Steidl, S., Neumann, J., Coulibaly, C., Holznagel, E., Holzammer, S., Norley, S., Cichutek, K.
(2002). Engineered CD4- and CXCR4-Using Simian Immunodeficiency Virus from African Green Monkeys Is Neutralization Sensitive and Replicates in Nonstimulated Lymphocytes. J. Virol.
76: 10627-10636
[Abstract]
[Full Text]
-
Cicala, C., Arthos, J., Selig, S. M., Dennis, G. Jr., Hosack, D. A., Van Ryk, D., Spangler, M. L., Steenbeke, T. D., Khazanie, P., Gupta, N., Yang, J., Daucher, M., Lempicki, R. A., Fauci, A. S.
(2002). HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc. Natl. Acad. Sci. USA
99: 9380-9385
[Abstract]
[Full Text]
-
Liu, N. Q., Lossinsky, A. S., Popik, W., Li, X., Gujuluva, C., Kriederman, B., Roberts, J., Pushkarsky, T., Bukrinsky, M., Witte, M., Weinand, M., Fiala, M.
(2002). Human Immunodeficiency Virus Type 1 Enters Brain Microvascular Endothelia by Macropinocytosis Dependent on Lipid Rafts and the Mitogen-Activated Protein Kinase Signaling Pathway. J. Virol.
76: 6689-6700
[Abstract]
[Full Text]
-
Popik, W., Alce, T. M., Au, W.-C.
(2002). Human Immunodeficiency Virus Type 1 Uses Lipid Raft-Colocalized CD4 and Chemokine Receptors for Productive Entry into CD4+ T Cells. J. Virol.
76: 4709-4722
[Abstract]
[Full Text]
-
Marozsan, A. J., Torre, V. S., Johnson, M., Ball, S. C., Cross, J. V., Templeton, D. J., Quinones-Mateu, M. E., Offord, R. E., Arts, E. J.
(2001). Mechanisms Involved in Stimulation of Human Immunodeficiency Virus Type 1 Replication by Aminooxypentane RANTES. J. Virol.
75: 8624-8638
[Abstract]
[Full Text]
-
Misse, D., Esteve, P.-O., Renneboog, B., Vidal, M., Cerutti, M., St Pierre, Y., Yssel, H., Parmentier, M., Veas, F.
(2001). HIV-1 glycoprotein 120 induces the MMP-9 cytopathogenic factor production that is abolished by inhibition of the p38 mitogen-activated protein kinase signaling pathway. Blood
98: 541-547
[Abstract]
[Full Text]